tbuckley/cabot-search huggingface dataset:
A Prospective Study of Persons with the Early Repolarization Normal Variant Electrocardiogram
Authors: Arthur L. Klatsky, Mary Anne Armstrong, Rudolph Oehm, Robert A. Cooper, Natalia Udaltsova
Journal: Circulation (2001)

P30 Sometimes confused with abnormal electrocardiogram (ECG) patterns, especially acute myocardial infarction, the poorly understood “early repolarization normal variant” (VAR) ECG has been considered benign, but, to our knowledge, has not been studied in relationship to later cardiovascular (CV) problems. We collected 2081 possible VAR and normal (NORM) ECG’s from among those done at health examinations of 72,830 members of a pre-paid health care program in 1983-85. All ECG’s were reinterpreted independently as VAR, Borderline, or NORM by 2 cardiologists blinded to all identifying and clinical data; agreement by both was required for categorization as VAR. Comparisons of subsequent hospitalizations and deaths through 1998 among all 72,830 examinees used Cox proportional hazards models with 7 covariates. Outpatient diagnoses were available from 1995 through 1999 among a subset of 45,528 examinees still in the program in 1995; these were compared in sex &amp; age-stratified groups by chi-square tests. The blinded readings yielded 670 VAR ECG s, 330 borderline ECG s, and 1081 NORM ECG s. Comparison of VAR to NORM showed increased VAR proportions of men, persons &lt; 40 years old, and blacks or Asians (all with p&lt;0.001). Among 21,826 persons hospitalized in the entire cohort there were 136 with VAR; among 7974 persons who died there were 37 with VAR; among 15,422 persons with outpatient diagnoses there were 95 with VAR. No significant differences in risk for VAR vs all persons were found for hospitalization or death for all causes, CV causes, or non-CV causes. For outpatient diagnoses, persons with VAR had lower rates/1000 persons than the entire population for any CV diagnosis (339/1000 for all; 256/1000 for VAR; p &lt; 0.001). Diagnosis rates among VAR were significantly lower for hypertension (p &lt; 0.02) arrhythmias (p &lt; 0.01) and non-specific CV symptoms (p &lt; 0.05) and also were nonsignificantly lower among VAR for coronary disease, cardiomyopathy, heart failure, stroke, and valvular disease. These data confirm the benign nature of VAR, suggesting that VAR not only carries no increased risk for development of CV conditions but may be associated with decreased CV risk.
T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections
Authors: C Ferrari
Journal: Hepatology (1994)

Twenty-nine patients with chronic hepatitis C and 15 asymptomatic hepatitis C virus antibody–positive subjects who clinically recovered from hepatitis C virus infection were studied for their peripheral blood lymphomononuclear cell proliferative response to hepatitis C virus structural and nonstructural antigens (core, envelope, nonstructural 4 and nonstructural 5) expressed in yeast as superoxide dismutase fusion proteins, in an initial attempt to define some of the features of the virus-specific immune response. Hepatitis C virus core was the most immunogenic antigen for human leukocyte antigen class II–restricted T cells in both groups of patients studied, and the proliferative response to it was the most vigorous and the most frequently expressed in comparison with the other antigens tested. The specificity of the results was supported by the lack of response to hepatitis C virus antigens by healthy uninfected controls and confirmed by recognition of recombinant core proteins of different origin (yeast and baculovirus) by polyclonal T-cell lines produced by T-cell stimulation with yeast-derived core. Each of the antigens tested was able to induce significant although variable levels of proliferative response, indicating that all can be immunogenic at the T-cell level. Significant proliferative responses to core, nonstructural 4 and nonstructural 5 antigens were more frequently detected in subjects who were able to eradicate infection than in patients with chronic hepatitis C, although the difference was statistically not significant. No difference was observed between the two groups of patients with respect to the response to the putative envelope antigens. (Hepatology 1994;19:286–295).
Chiropractic
Authors: Ronald L. Fredrickson
Journal: Annals of Internal Medicine (2002)

Letters15 October 2002ChiropracticRonald L. Fredrickson, MSRonald L. Fredrickson, MSRoseville, CA 95747Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-8-200210150-00027-w1 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Chiropractic is a many-splintered thing, a fact that was glossed over in the paper by Drs. Meeker and Haldeman (1). In my area, we have chiropractors who belong to the National Upper Cervical Chiropractic Association, a group that believes that manipulation of the upper cervical vertebrae is the answer. Another chiropractor advertises his use of quantum connective healing. Still another uses network spinal analysis, a practice so strange that chiropractors who don't use it have tried to have it banned. The broadest division in the profession is that of the “straights” versus the “mixers.” The former believe ...Reference1. Meeker WC, Haldeman S. Chiropractic: a profession at the crossroads of mainstream and alternative medicine. Ann Intern Med. 2002;136:216-27. [PMID: 11827498] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Roseville, CA 95747 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoChiropractic: A Profession at the Crossroads of Mainstream and Alternative Medicine William C. Meeker and Scott Haldeman Chiropractic Edzard Ernst Chiropractic Daniel J. Fink Chiropractic Ludmil A. Chotkowski Chiropractic William C. Meeker and Scott Haldeman Metrics 15 October 2002Volume 137, Issue 8Page: W1KeywordsAcupunctureChiropracticNetwork analysisVertebraeVitamins ePublished: 15 October 2002 Issue Published: 15 October 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
KIDNEY DISEASE AND ABUSE OF ANALGESICS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
INNV-29. EXPERIENCE WITH TTFIELDS (OPTUNE®) IN PEDIATRIC HIGH GRADE GLIOMA PATIENTS IN ISRAEL
Authors: Helen Toledano, Gadi Abebe Campino, Rina Dvir, Sergei Postovsky, Michal Yalon
Journal: Neuro-Oncology (2018)

TTFields are an established treatment for glioblastoma (GBM) in adults and have been shown to prolong OS, PFS and long-term survival with minimal side-effects. TTFields are not yet approved for children and the device (Optune®) was provided on a compassionate basis to all patients in this case series. We report our experience with TTFields at 4 major pediatric oncology centers in Israel. Since September 2017 Optune has been offered to 7 pediatric patients of whom 5 (3 female, 2 male) gave consent immediately. These patients were aged 11.1 - 17.7 years at time of diagnosis. 4/5 had a midline diffuse glioma H3.3K27M positive and started Optune together with temozolomide following biopsy/subtotal resection and radiation. The fifth patient had a gross total resection of a right parietal GBM positive for the H3.3G34R mutation. He was treated with radiation and adjuvant temozolomide and had a multifocal right sided relapse at 20 months, and was then treated with Avastin and Optune. Two patients reported device-related mild itchy skin, which was easily treated topically. Four patients continued all normal activities despite carrying the device during school attendance, trips abroad and even at a waitressing job. One male refused to attend school and continues home learning. Three patients had programmable shunts, without any interference with Optune. Compliance was >90% in 3 patients, 80% in 1 individual and 60% in the relapsed patient. 2/5 patients have stopped treatment due to progression after 86 and 142 days on Optune, however all patients are still alive at the time of the report. In summary TTFields is a feasible and tolerable treatment even in children as young as 11 years. TTFields had no additional systemic side-effects and showed good acceptance rate. Further studies in pediatric patients are needed to evaluate efficacy in pediatric high-grade glioma.
Hookworm Infections
Authors: Franklin P. Holman
Journal: JAMA (1963)

<h3>To the Editor:</h3> —In the Sept 14 issue ofThe Journal(<b>185</b>:874) it was stated in an article by Dr. Harry Most that hookworm infections are extremely rare in the US at the present time. This may be true in New York City but here in a rural community in Florida it is definitely not. During the past year, I have seen on the average at least one case of hookworm a week in doing a series of three routine stool examinations on all children who come into the office. In fact, hookworm is the most common parasite I have seen (excluding pinworm).
Presidential Courage
Authors: Phil Gunby
Journal: JAMA (1980)

In this world of fragile political relationships, it sometimes seems as if every sneeze or sniffle from a President of the United States is cause for a news bulletin and a shockwave through Wall Street. Not only is such reporting about the President's health virtually instantaneous, but in recent years it also has gone into increasingly intimate detail. The public now reads and hears accounts of Presidential anatomical and physiological functions (or malfunctions) that Chief Executives of the past probably did not even admit to themselves, much less to everyone else in the world. In fact, quite the opposite used to be true. Perhaps the most famous example is the secret surgery aboard a yacht in New York's East River 87 years ago, during which a verrucous carcinoma was removed from President Grover Cleveland's upper jaw. The press was suspicious, but the full story was not revealed until 20 years
Daniel Turnberg
Authors: Caroline Richmond
Journal: BMJ (2007)

Innovator in perinatal mental healthDiana Riley was a key figure in obstetric liaison psychiatry and perinatal mental health.She researched and published widely over 36 years, including works for health professionals and lay readers on postnatal depression and drug addiction in pregnancy.Diana instituted one of the first mother and baby mental health units in the country, at St John's Hospital, Stone, to care for mothers with postnatal depression without separating them from their babies-a revolutionary idea at the time.She established and supervised psychotherapy groups for mothers with postnatal depression in Buckinghamshire, and developed expertise in drug addiction in pregnancy while working and teaching at University College Hospital, London.She was also a prime mover in one of the earliest dedicated pre-senile dementia units in the country, leading a multidisciplinary team at St John's Hospital, Stone.Brought up in a deprived area of London, Diana was influenced by seeing people unable to afford proper medical treatment.Her conviction that one must add to the sum of human health and happiness informed her work and her relationships with family, friends, and the wider community.After qualifying and marrying, she was a locum in general practice during 1956-60, producing a child a year.She cared for the families of the Royal Air Force at RAF Halton
OP0068 EFFICACY AND SAFETY OF TNF-Α ANTAGONISTS AND TOCILIZUMAB IN TAKAYASU ARTERITIS: MULTICENTER WORLDWIDE RETROSPECTIVE STUDY OF 209 PATIENTS
Authors: A. Mekinian, L. Biard, L. Dagna, P. Jégo, C. Salvarani, M. Sergey, O. Espitia, S. Sciascia, P. Hernan, P. Cacoub, O. Fain, D. Saadoun
Journal: Annals of the Rheumatic Diseases (2021)

Background: In this large worldwide TAK registry, we report 209 patients treated with TNF-α antagonists and tocilizumab aiming to compare their safety and efficacy, and determine the predictive factors of treatment response and relapse. Objectives: To assess safety and efficacy of TNF-α antagonists and tocilizumab in patients with Takayasu arteritis (TAK). Methods: We conducted a retrospective multicenter study in referral centers from France, Italy, Spain, Israel, Japan, Tunisia and Russia about biological-targeted therapies in TAK during the period from January 2017 to September 2019 for the data collection. Results: Two-hundred nine patients with TAK [median age of 29 years [7-62], and 186 (89%) females] were included. They received either TNF-α antagonists [n=132 (63%) with 172 lines; infliximab (n=109), adalimumab (n=45), golimumab (n=8), certolizumab (n=6) and etanercept (n=5)], or tocilizumab [n=77 (37%) with 121 lines; intravenous and subcutaneous in 95 and 26 cases, respectively]. A complete response at 6 months was evidenced in 101/152 (66%) on TNF-α antagonists and 75/107 (70%) on tocilizumab, respectively. Age ≥ 30 years [OR= 2.09 [1.09; 3.99]] was associated with complete response, whereas vascular signs [0.26 [0.1;0.65]], baseline prednisone ≥ 20 mg/day [0.51 [0.28;0.93]] were negatively associated with the complete response to TNF-α antagonists or tocilizumab. During a median follow-up of 36 months, 103 relapses were noted. Supra-aortic branches and thoracic aorta involvements [HR 2.44 (1.06;5.65) and 3.66 (1.18;11.4), respectively], and systemic signs at baseline [HR 2.01 (1.30;3.11)] were significantly associated with relapse. The cumulative incidence of treatment discontinuation and relapse were similar in TNFα antagonists and tocilizumab. Fifty-eight (20%) adverse effects occurred on biological-targeted therapies of whom 37 (21%) and 21 (17%), (p=0.4) on TNF-α antagonists and tocilizumab, respectively Conclusion: This large multicenter study shows high efficacy of biological-targeted treatments in refractory TAK. Efficacy, relapse and drug retention rate were equivalent with TNF-α antagonists and tocilizumab. Disclosure of Interests: None declared
Urinary Nickel Excretion in Populations Living in the Proximity of Two Russian Nickel Refineries: A Norwegian-Russian Population-Based Study
Authors: Tone Smith-Sivertsen, Valeri Tchachtchine, Eiliv Lund, Vladimir Bykov, Yngvar Thomassen, Tor Norseth
Journal: Environmental Health Perspectives (1998)

The Russian nickel refineries located in the cities of Nikel and Zapolyarny close to the Norwegian border are responsible for extensive sulfur dioxide and nickel pollution, as well as severe ecological damage in both countries. The aim of our study was to investigate human nickel exposure in the populations living on both sides of the Norwegian-Russian border. The design was a cross-sectional population-based study of adults aged 18-69 years residing in Sor-Varanger municipality, Norway, and Nikel and Zapolyarny, Russia, during 1994 and 1995. Individual exposure to nickel was assessed by measurements of nickel in urine using electrothermal atomic absorption spectrometry. For controls, urine was collected from adults in the Russian cities of Apatity and Umba (Kola Peninsula) and the Norwegian city of Tromso, all of which are locations without nearby point sources of nickel. Altogether 2,233 urine specimens were analysed for nickel. People living in Nikel had the highest concentrations (median 3.4 microg/l), followed by Umba (median 2.7 microg/l), Zapolyarny (median 2.0 microg/l), Apatity (median 1.9 microg/l), Tromso (median 1.2 microg/l), and Sor-Varanger (median 0.6 microg/l). Regardless of geographical location, the Russian study groups all had a higher urinary-nickel average than those in Norway (p<0.001). With the exception of Nikel, neither the Russian nor the Norwegian urinary-nickel levels were associated with residence location near a Russian nickel refinery. We concluded that industrial nickel pollution alone could not explain the observed discrepancy between Norway and Russia; we also discuss other possible nickel exposure sources that may account for the high urinary levels found in Russia.
American College of Physicians Guidelines on Cholesterol Screening
Authors: Holly L. Thacker
Journal: Annals of Internal Medicine (1996)

Letters15 December 1996American College of Physicians Guidelines on Cholesterol ScreeningHolly L. Thacker, MDHolly L. Thacker, MDCleveland Clinic Foundation, Cleveland, OH 44195.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-125-12-199612150-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The recently published “Guidelines for Using Serum Cholesterol, High-Density Lipoprotein Cholesterol, and Triglyceride Levels as Screening Tests for Preventing Coronary Heart Disease in Adults” [1] should have been titled “Guidelines for Using Serum Cholesterol, High-Density Lipoprotein Cholesterol, and Triglyceride Levels as Screening Tests for Preventing Coronary Heart Disease in Men.” Premature menopause without the benefit of estrogen replacement therapy is an established risk factor for atherosclerosis and should have been included in the list of risk factors. Under the new American College of Physicians guidelines, a 44-year-old diabetic woman with premature or surgical menopause who is not ...References1. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med. 1996; 124:515-7. Google Scholar2. The effects of estrogen or estrogen/progesterone regimens on heart disease: risk factors in postmenopausal women. The PEPI Trial. The Writing Group for the PEPI Trial. JAMA. 1995; 273:199-208. Google Scholar Author, Article, and Disclosure InformationAffiliations: Cleveland Clinic Foundation, Cleveland, OH 44195. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByThe importance of dietary calcium consumption in two species of semi-terrestrial grapsoid crabs 15 December 1996Volume 125, Issue 12Page: 1008-1009KeywordsCholesterolCoronary heart diseaseEstrogen replacement therapyHigh density lipoprotein cholesterolHormone replacement therapyMedical risk factorsMenopauseScreening guidelinesStable coronary artery diseaseVascular diseases Issue Published: 15 December 1996 CopyrightCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
A CASE OF BORAX POISONING
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Urologists Present Positive Evidence for Early Test
Authors: M. Mitka
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Insulin pump therapy reconsidered
Authors: F. K. Thorp
Journal: JAMA (1986)

It has been recognized for some time that the traditional methods of treating type I diabetes mellitus (insulin-dependent diabetes mellitus) with a program of one or two daily insulin injections and diet and exercise planning are quite imperfect. With the advent of home blood glucose—monitoring techniques and glycosylated hemoglobin determinations, it is evident that many persons with diabetes have a degree of hyperglycemia sufficient to contribute to development of devastating longterm complications. Ultimately, it is hoped that advances in the field of islet cell transplantation or pancreas transplantation will allow more physiologic control of blood glucose levels. In the interim, efforts to improve insulin administration have resulted in the development of a myriad of electromechanical pump devices. These insulin infusion devices are designed to mimic the natural pattern of insulin release by providing both a continuous, variable small supply of insulin and extra boluses of insulin prior to eating. Now
Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Classical Risk Factors and Minimal Residual Disease (MRD). Interim Results of the PETHEMA ALL-AR-03 Trial.
Authors: Josep Ribera, Albert Oriol, Mireia Morgades, Josep Sarrá, Salut Brunet, Andreu Llorente, Ramon Guardia, Ricardo Parody, Teresa Bernal, Jordi Esteve, Miguel Sanz, Eloy Del Potro, Juan Bergua, Maria-Jose Moreno, Carlos Grande, Javier Bueno, Antonia Cladera, María-Carmen Fernández, Raimundo García-Boyero, Arancha Bermúdez, Evarist Feliu
Journal: Blood (2006)